Latest Infliximab Stories
An investigational drug currently under FDA review for the treatment of rheumatoid arthritis has now shown positive results in patients with moderate-to-severe ulcerative colitis.
New research confirms no significant difference in the rates of death among patients with rheumatoid arthritis (RA) who were exposed to one of several TNF inhibitors used to treat RA, adalimumab (Humira), etanercept (Enbrel), and infliximab (Remicade).
The latest regional Outpatient Infusion Center officially opened this week at Stafford Hospital, Mary Washington Healthcare. Stafford, VA (PRWEB) June 22, 2012
A new Phase III study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that patients treated with certolizumab pegol (CZP) were twice as likely to meet the primary endpoint of ACR20 response at week 12 than those on placebo: 58% on CZP200mg Q2W; and 51.9% on CZP 400 mg Q4W compared to 24.3% on placebo.
New research being presented at Digestive Disease Week® (DDW) offers key insights into the prevention and treatment of bowel diseases, which affect millions of people worldwide.
- The parings of haberdine; also, any kind of fragments.